These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 38783925)

  • 21. Repurposing Tamoxifen as Potential Host-Directed Therapeutic for Tuberculosis.
    Boland R; Heemskerk MT; Forn-Cuní G; Korbee CJ; Walburg KV; Esselink JJ; Carvalho Dos Santos C; de Waal AM; van der Hoeven DCM; van der Sar E; de Ries AS; Xie J; Spaink HP; van der Vaart M; Haks MC; Meijer AH; Ottenhoff THM
    mBio; 2023 Feb; 14(1):e0302422. PubMed ID: 36475748
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Revolutionizing control strategies against Mycobacterium tuberculosis infection through selected targeting of lipid metabolism.
    Kim H; Shin SJ
    Cell Mol Life Sci; 2023 Sep; 80(10):291. PubMed ID: 37704889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: current status and future prospects.
    Yew WW
    Kekkaku; 2011 Jan; 86(1):9-16. PubMed ID: 21401001
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of New Therapeutics to Meet the Current Challenge of Drug Resistant Tuberculosis.
    Sheikh BA; Bhat BA; Mehraj U; Mir W; Hamadani S; Mir MA
    Curr Pharm Biotechnol; 2021; 22(4):480-500. PubMed ID: 32600226
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010-2020 Review.
    Angula KT; Legoabe LJ; Beteck RM
    Pharmaceuticals (Basel); 2021 May; 14(5):. PubMed ID: 34068171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Role of Proline-Proline-Glutamic Acid (PPE) Proteins in Mycobacterium tuberculosis Virulence: Mechanistic Insights and Therapeutic Implications.
    Ilesanmi A; Odeniran OM; Tatsipie L; Osam Duodu E; Ankrah PK
    Cureus; 2024 Jan; 16(1):e51955. PubMed ID: 38333477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antitubercular drugs: possible role of natural products acting as antituberculosis medication in overcoming drug resistance and drug-induced hepatotoxicity.
    Rana HK; Singh AK; Kumar R; Pandey AK
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Mar; 397(3):1251-1273. PubMed ID: 37665346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Latent TB Infection (LTBI) - Mycobacterium tuberculosis pathogenesis and the dynamics of the granuloma battleground.
    Rao M; Ippolito G; Mfinanga S; Ntoumi F; Yeboah-Manu D; Vilaplana C; Zumla A; Maeurer M
    Int J Infect Dis; 2019 Mar; 80S():S58-S61. PubMed ID: 30822547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pediatric Drug-Resistant Tuberculosis: The Current and Future Prospects for Management and Prevention.
    Dharmapalan D; Mane SS
    Pathogens; 2023 Nov; 12(11):. PubMed ID: 38003836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Using a Heat Diffusion Model to Detect Potential Drug Resistance Genes of
    Cui ZJ; Zhang WT; Zhu Q; Zhang QY; Zhang HY
    Protein Pept Lett; 2020; 27(8):711-717. PubMed ID: 32167422
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic host-directed strategies to improve outcome in tuberculosis.
    Young C; Walzl G; Du Plessis N
    Mucosal Immunol; 2020 Mar; 13(2):190-204. PubMed ID: 31772320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cubosome Lipid Nanocarriers As a Drug Delivery Vehicle for Intracellular
    Sarkar S; Dyett B; Lakic B; Ball AS; Yeo LY; White JF; Soni S; Drummond CJ; Conn CE
    ACS Appl Mater Interfaces; 2023 May; 15(18):21819-21829. PubMed ID: 37018059
    [No Abstract]   [Full Text] [Related]  

  • 34. Antitumor therapy for breast cancer: Focus on tumor-associated macrophages and nanosized drug delivery systems.
    Zhan C; Jin Y; Xu X; Shao J; Jin C
    Cancer Med; 2023 May; 12(10):11049-11072. PubMed ID: 36794651
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transcriptomic Signatures Predict Regulators of Drug Synergy and Clinical Regimen Efficacy against Tuberculosis.
    Ma S; Jaipalli S; Larkins-Ford J; Lohmiller J; Aldridge BB; Sherman DR; Chandrasekaran S
    mBio; 2019 Nov; 10(6):. PubMed ID: 31719182
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alginate-Capped Silver Nanoparticles as a Potent Anti-mycobacterial Agent Against
    Chen CC; Chen YY; Yeh CC; Hsu CW; Yu SJ; Hsu CH; Wei TC; Ho SN; Tsai PC; Song YD; Yen HJ; Chen XA; Young JJ; Chuang CC; Dou HY
    Front Pharmacol; 2021; 12():746496. PubMed ID: 34899300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amorphous Drug Nanoparticles for Inhalation Therapy of Multidrug-Resistant Tuberculosis.
    Rudolph D; Redinger N; Schwarz K; Li F; Hädrich G; Cohrs M; Dailey LA; Schaible UE; Feldmann C
    ACS Nano; 2023 May; 17(10):9478-9486. PubMed ID: 37160267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The significance of persisters in tuberculosis drug discovery: Exploring the potential of targeting the glyoxylate shunt pathway.
    Negi A; Sharma R
    Eur J Med Chem; 2024 Feb; 265():116058. PubMed ID: 38128237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. When the Lightning Strikes Twice: Navigating the Complex Terrain of Cerebral Tuberculosis.
    Sérvio R; Silva AR; Fernandes S; Tavares R; Rodrigues P
    Cureus; 2024 Jan; 16(1):e52090. PubMed ID: 38344590
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent advances in oxazolidinones as antituberculosis agents.
    Lu H; Wang H; Zhao H; Zhang D
    Future Med Chem; 2022 Aug; 14(15):1149-1165. PubMed ID: 35866418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.